ESTRO 2024 - Abstract Book

S4981

Physics - Radiomics, functional and biological imaging and outcome prediction

ESTRO 2024

Our ROI-specific assessment assisted by TRAQinform IQ technology identified a subset of patients suspicious of oligoprogressive disease in whom it may be feasible to target progressing ROI. The results indicate that quantitative features extracted from 18 F-FDG PET/CT imaging have the potential for application in selecting lesions for ablative radiation therapy. The addition of machine-learning tools to assist in the identification of oligoprogressive disease warrants further investigation in a prospective setting. Ongoing and future clinical trials will be important to further validate a lesion-level response evaluation approach to patient care.

Keywords: melanoma, oligoprogressive, machine-learning

References:

1. Chicas-Sett, R., et al., Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. Clin Transl Radiat Oncol, 2018. 9: p. 5-11. 2. Liniker, E., et al., Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology, 2016. 5(9): p. e1214788. 3. Koller, K.M., et al., Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol Ther, 2017. 18(1): p. 36 42. 4. Aboudaram, A., et al., Concurrent radiotherapy for patients with metastatic melanoma and receiving anti programmed-death 1 therapy: a safe and effective combination. Melanoma Res, 2017. 27(5): p. 485-491. 5. Sundahl, N., et al., Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. Int J Radiat Oncol Biol Phys, 2019. 104(4): p. 828-835. 6. Kroeze, S.G.C., et al., Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium. The Lancet Oncology, 2023. 24(3): p. e121-e132. 7. Tagliaferri, L., et al., Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother, 2022. 18(3): p. 1903827. 8. Zhang, Z., et al., Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduction and Targeted Therapy, 2022. 7(1): p. 258. 9. Ayati, N., et al., The value of (18)F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging, 2021. 48(2): p. 428-448. 10. Sachpekidis, C., et al., The prognostic value of [(18)F]FDG PET/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria. Eur J Nucl Med Mol Imaging, 2023. 50(9): p. 2699-2714. 11. Hiniker, S.M., et al., A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys, 2016. 96(3): p. 578-88.

692

Digital Poster

T 1 & T 2 mapping on a Unity MRL in a clinically feasible timeframe